THE RELATIONSHIP BETWEEN POTENTIAL ANTIDIABETIC DRUG INTERACTIONS AND CLINICAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.36858/ipj.v2i2.95Keywords:
Diabetes Mellitus, Drug Interaction, Clinical Outcomes, Potential Drug InteractionsAbstract
ABSTRACT
Diabetes mellitus is a chronic disease that requires long-term care with an increasing mortality rate. In type 2 DM patients, the potential for drug interactions is quite high. Previous research showed that 81% of type 2 DM patients are at risk of experiencing drug interactions. Several studies in hospitals show that some patients still do not achieve optimal clinical outcomes. This study aims to analyze the relationship between potential interactions of antidiabetic drugs and clinical outcomes of type 2 DM patients undergoing antidiabetic therapy. The method used was cross-sectional with retrospective data collection from medical records. Relationship analysis was conducted using the Chi-Square test. The research population consisted of all medical records of patients diagnosed with type 2 DM, and the sample included 118 medical records that met the inclusion criteria. The research results showed that the most commonly used diabetes combination therapy was found in 60 patients (50.85%). The most commonly used single antidiabetic drug was glimepiride, with 35 patients (29.66%). The most frequent combination of antidiabetic drugs was pioglitazone with glimepiride, with 21 patients (17.78%). Potential drug interactions occurred in 55.93% of patients, with the majority being of moderate severity at 95.69%. The most common interaction was between gliclazide and metformin at 10.34%. A total of 98 patients (83.1%) had controlled clinical outcomes. The Chi-Square test resulted in a p-value of 0.025 (<0.05), indicating a significant relationship between potential drug interactions and clinical outcomes of type 2 DM patients. Based on the results of this study, it can be concluded that there is a significant relationship between potential antidiabetic drug interactions and clinical outcomes of type 2 DM patients at Hospital "X". This study only identified the potential for interactions without directly evaluating patient complaints or clinical impacts.
Keywords: Diabetes Mellitus, Drug Interaction, Clinical Outcomes, Potential Drug Interactions
References
Az-zuhra, I., Permana, D., & Arsyad, M. (2024). Penggunaan Obat Antihipertensi Sebagai Terapi Hipertensi pada Pasien Geriatri Rawat Jalan di Rsud Dr . Drajat Prawiranegara Serang dan Tinjauannya Menurut Pandangan Islam The Use of Antihypertension Drugs as Hypertension Therapy in Outpatient Geriatric Pa. Junior Medical Journal, Volume 2, No. 7, Maret 2024, 2(7), 820–830.
Dewi, R., Hadriyati, A., & Situngkir, E. N. (2025). Analisis Interaksi Obat Antidiabetik terhadap Clinical Outcome Pasien DM Tipe 2 di RS X Jambi. Jurnal Akademika Baiturrahim Jambi (JABJ), Maret 2025, 14(1): 80-92 Available Online Http://Jab.Ubr.Ac.Id/Index.Php/Jab DOI : 10.36565/Jab.V14i1.898 Analisis, 14(1), 80–92.
Fitriyani, F., Andrajati, R., & Trisna, Y. (2021). Analisis Efektivitas-Biaya Terapi Kombinasi Metformin-Insulin dan Metformin-Sulfonilurea pada Pasien Rawat Jalan dengan Diabetes Melitus Tipe 2 di RSUPN Dr. Cipto Mangunkusumo. Indonesian Journal of Clinical Pharmacy, 10(1), 10. https://doi.org/10.15416/ijcp.2021.10.1.10
Lazar, S., Ionita, I., Delia, R., & Bogdan, T. (2024). How to Measure Glycemic Variability ? A Literature Review. Medicina 2024, 60, 61. Https://Doi.Org/10.3390/Medicina60010061, 1–10.
Natanael, J., Ervina, D., Rani, H., & Oktafany. (2024). Literatur Review: Kajian Potensi Interaksi Obat Antidiabetes Pada Pasien Diabetes Melitus Tipe 2 Dengan Komplikasi Hipertensi. 2(6), 201–206.
Pambagyanik, A. A., & Lorensia, A. (2023). Analisis Cost -Effectiveness Kombinasi Glimepiride-Metformin Dengan Glimepiride-Pioglitazone pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan. 5(2), 107–116. https://doi.org/10.24123/mpi.v5i2.5541
Pengurus Besar Perkumpulan Endokrinologi Indonesia (PERKENI). (2024). Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia Tahun 2024. Pb Perkeni.
PERKENI, 2021. (2021). Pengelolaan Dan Pencegahan Diabetes Melitus TIPE 2 Di Indonesia2021.
Prastiya, U., Dyan, M., & Rosida. (2022). Potensi Interaksi Obat Bisoprolol Pada Pasien BPJS Rawat Jalan Di Poli Jantung Rumah Sakit Al Huda Banyuwangi. Jurnal Ilmiah Farmasi AKFAR, Vol. 5 No. 2 Desember 2022 PISSN: 2503-4707; EISSN: 2615-756X, 64–71.
Sasindi, D. A., Shinta, M., & Sholihatil, H. (2025). POTENSI INTERAKSI OBAT ANTIDIABETES ORAL PADA PASIEN. Jurnal Ilmiah Farmasi Akademi Farmasi Vol. 8 No. 1, Juli 2025 PISSN: 2503-4707; EISSN: 2615-756X POTENSI, 8(1), 172–185.
Sugiyono, Siwi, P., & Shalahuddin, A. M. (2025). The Relationship Between Antidiabetic Drug Interactions And Clinical Outcomes In Type 2 Diabetes Mellitus Patients. Ilmu Media Kesehatan Vol. 14, No. 1, April 2025 Https://Doi.Org/10.30989/Mik.V14i1.1479, 082.
Susanti, N., Syahpira, D. D., Aulia, S. T., & Syahmala, A. R. (2024). Hubungan Usia Pada Kejadian Diabetes Melitus Tipe 2 Dengan Pendekatan Stepwise. JURNAL KESEHATAN TAMBUSAIVolume 5, Nomor 2, Juni 2024, 5, 4283–4288.
Wuryandari, H., Raising, R., & Widiarini, R. (2021). Analisis Efektivitas Biaya Terapi Antidiabetes Oral Kombinasi Pada Pasien Diabetes Melitus Tipe 2 Di Rsud Kota Madiun Tahun 2020. Duta Pharma Journal, 1(2), 1–7. https://doi.org/10.47701/djp.v1i2.1211
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Iski Weni Pebriarti, Ikhlashul Badriyah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
